Immunocore Holdings plc reported its financial results for the fourth quarter and full year ended December 31, 2024. KIMMTRAK net sales reached $84.1 million in Q4 2024 and $310.0 million for the full year, with continued growth expected in 2025. The company is advancing its KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications. The PRAME portfolio is also progressing, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial. The company is also enrolling patients in a Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC. The first patient was dosed in the Phase 1 trial of IMC-P115C (PRAME-A02-HLE). The first patient was dosed in the Phase 1/2 trial of IMC-R117C (PIWIL1) in colorectal and other gastrointestinal cancers. Initial Phase 1 multiple ascending dose HIV data for IMC-M113V will be presented in Q1 2025, and Phase 1 single ascending dose HBV data for IMC-I109V in 2H 2025. CTA/IND is on track for IMC-S118AI (type 1 diabetes candidate) in 2H 2025 and for IMC-U120AI (atopic dermatitis candidate) in 2026. Cash, cash equivalents, and marketable securities totaled $820.4 million as of December 31, 2024. The company repaid its Pharmakon loan of $50.0 million in November 2024. Net loss for the fourth quarter of 2024 was $23.8 million, and the full year net loss for 2024 was $51.1 million.